In fact all of the big players are already dabbling with artificial intelligence in pharma use-case scenarios (more below). According to The State of AI: Artificial Intelligence in Business, 62 percent of businesses are thinking of investing in AI soon. In fact, 20 percent of the businesses...
90% of clinical drug candidates fail to reach approval, driving costs of drug development to an estimated $1.4 billion. AI has wider potential to cut costs of the industry’s R&D spend, which for the largest 10 pharma companies is $67 billion (40% of sec
Artificial intelligence (AI) has achieved human-level capabilities and continues to rapidly improve. For the pharmaceutical industry, AI can improve decision-making and transform the quest for better medicines. The keys are investing in data management and in internal AI talent who can create value ...
Just think, these pharma and biomedicine companies are already proved their strength in the global drug development industry. Then, why they are investing in AI technology or artificial intelligence in pharmaceutical manufacturing? The simple answer is that they are trying to become more competitive an...
Brad Gallagher:My understanding of these attacks is that some companies are still utilizing legacy systems that are outdated and are not compliant with current security standards. This creates vulnerabilities. Investing in advanced technologies, education, and training are paramount to strengthening this ...
Investing in R&D or partnership with external technology solution providers on a variety of use cases promises to make better use of scientific experts’ time, as use of their time shifts from initial drafting to strategic thinking in collaboration with clinical development professionals...
and loss of expensive api materials. this will help reduce operating costs. enabling these applications calls for investing in aggregating data from multiple manufacturing systems and thoughtful placement of sensors across the manufacturing floor. some early movers are already beginning to report benefits...
In 2024, the spotlight in R&D is set to return to oncology, with a focus on leveraging AI in clinical trials. Stay updated on the latest advancements in this field.
Many companies are investing in advanced AI-driven translational science programs to more efficiently define targets and design therapeutics to meet these needs. While AI-driven drug discovery is promising, multiple products using this technology have failed to meet clinical endpoints over the past year...
However, most companies today are stuck in a transitional phase with generative AI where enthusiasm outstrips impact. Here’s what we’re hearing from leaders in life sciences: Companies are investing in disjointed use cases that create productivity gains in isolated pockets but fail to drive the ...